Home > Gastroenterology > DDW 2024 > Eosinophilic Oesophagitis Treatments and Outcomes > Budesonide demonstrates efficacy in eosinophilic oesophagitis

Budesonide demonstrates efficacy in eosinophilic oesophagitis

Presented by
Prof. Edoardo Savarino, University of Padua, Italy
Conference
DDW 2024
Doi
https://doi.org/10.55788/077d0484
Budesonide, a locally acting corticosteroid, demonstrated efficacy as an induction treatment of eosinophilic oesophagitis (EoE) in a real-life setting, considering clinical, endoscopic, and histological outcomes at 12 weeks. Moreover, budesonide showed a favourable safety profile.

This multicentre, prospective, observational study enrolled 152 adult patients (121 men; mean age 35 years) diagnosed with EoE across 8 Italian centres and 1 Israeli centre [1]. Participants received budesonide 1 mg twice daily as induction treatment for at least 12 weeks. Outcomes were evaluated after 12 weeks using the Endoscopic Reference Score (EREFS) for endoscopic appearance, the peak eosinophilic infiltration for histological assessment, and the Dysphagia Symptom Questionnaire (DSQ) and Health-Related Quality of Life (HRQoL) questionnaire for clinical response. The primary endpoints were endoscopic and histological remission, along with improvements in dysphagia symptoms and quality-of-life.

The results shared by Prof. Edoardo Savarino (University of Padua, Italy) showed that 54% of the participants achieved endoscopic remission, with the mean EREFS score decreasing from 3.1 to 1.3 (P<0.001). The histological remission was observed in 91% of the participants, with a mean peak eosinophil count dropping from 33.3 eosinophils/high power field at baseline to 3.1 at week 12 (P<0.001).

Regarding the dysphagia symptom, the mean DSQ score significantly decreased from 20.3 to 4.8 (P=0.001), while the quality-of-life improved, with mean HRQoL scores increasing from 119.6 to 140 (P=0.02).

Side effects were reported in 14 out of 151 participants (9.2%), with 4 requiring treatment discontinuation.

This study confirms budesonide's efficacy in inducing remission in patients with EoE, significantly improving clinical, endoscopic, and histological outcomes. The safety profile was favourable, with minimal treatment discontinuations.


    1. Savarino EV, et al. Real-world evidence of the effectiveness and safety of orodispersible budesonide tablet for the treatment of eosinophilic esophagitis: a multicentre prospective study evaluating the induction period. Sa1293, DDW 2024, 18–21 May, Washington DC, USA.

Copyright ©2024 Medicom Medical Publishers



Posted on